Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thor Medical ASAFRA:8NN -1.04%28 EPS without NRI is €-0.02 as of Dec. 2025. GuruFocus rates FRA:8NN with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,168 Biotechnology companies, Thor Medical ASA ranks better than 89.38% on this metric.
Thor Medical ASA's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was €-0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.02.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 59.90% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 59.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Thor Medical ASA's EPS without NRI or its related term are showing as below:
FRA:8NN'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -93.7 Med: -0.3 Max: 82.3
Current: 59.9
During the past 13 years, Thor Medical ASA's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 82.30% per year. The lowest was -93.70% per year. And the median was -0.30% per year.
FRA:8NN's 3-Year EPS without NRI Growth Rate is ranked better than 89.38% of 1168
companies
in the Biotechnology industry
Industry Median: 16.4
vs FRA:8NN: 59.90
Thor Medical ASA's EPS (Diluted) for the
six
months ended in Dec. 2025 was €-0.01.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.02.
Thor Medical ASA's EPS (Basic) for the
six
months ended in Dec. 2025 was €-0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.02.
Thor Medical ASA (FRA:8NN) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thor Medical ASA EPS without NRI Related Terms
Thor Medical ASA EPS without NRI Historical Data
* Premium members only.
The historical data trend for Thor Medical ASA's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8NN vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, Thor Medical ASA's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thor Medical ASA PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thor Medical ASA's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Thor Medical ASA's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thor Medical ASA (FRA:8NN) has a EPS without NRI of €-0.02 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Thor Medical ASA and its competitors. According to the industry distribution chart, Thor Medical ASA ranks #124 out of 1168 companies in the Biotechnology industry, placing it in the top 10.6%.
Is Thor Medical ASA's EPS without NRI too high?
Thor Medical ASA's current EPS without NRI is €-0.02. Based on the distribution chart, Thor Medical ASA ranks #124 out of 1168 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Thor Medical ASA has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thor Medical ASA ranks #124 out of 1168 companies for EPS without NRI. This places Thor Medical ASA in the top 11% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Thor Medical ASA and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thor Medical ASA's current EPS without NRI is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current EPS without NRI of €-0.02. The current EPS without NRI is €-0.02. Thor Medical ASA's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current EPS without NRI is €-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
28GF Score
Get the complete analysis for FRA:8NN
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8NN has been successfully added to your 
